Background/Aim: Previous studies of nodenegative oral squamous cell carcinoma have shown a benefit of elective neck dissection compared to observation. Evidence for radiotherapy as single-modality elective treatment of the node-negative neck is so far lacking. Patients and Methods: In a retrospective material of 420 early-stage oral cancers from 2000 to 2016, overall survival, disease-free survival, and regional relapse-free survival were calculated with the Kaplan-Meier method. Results: At five years, overall survival was 59.7%, disease-specific survival was 77.2%, and regional relapse-free survival was 83.5%. Among those with adjuvant treatment of the neck after surgery of T1-T2 tumours during 2009-2016, regional relapse-free survival at five years was 85.7% for elective radiotherapy of the neck and 87.4% for elective neck dissection. Conclusion: Elective radiotherapy to the neck with a modern technique and adequate dose might be an alternative to neck dissection for patients with early-stage oral squamous cell cancer.The standard treatment of oral squamous cell carcinoma (OSCC) is surgery with adequate resection margins, with or without adjuvant radiotherapy. In clinically node-negative (cN0) cases, the frequency of subclinical nodal metastases ranges from about 16% to 26% (1-3). There are currently four ways to manage the neck in patients with cN0 OSCC: watchful waiting, elective neck dissection (END), elective radiotherapy of the neck (ERTN), and a combination of END and ERTN (4). The role of post-operative radiotherapy to the primary tumour site remains undetermined, although some evidence suggests that it reduces the risk of locoregional failure (5, 6). END has been shown to increase disease-free survival at three years from 45.9% to 69.5% and overall survival (OS) at three years from 67.5% to 80.0% in patients with early stage OSCC when compared to watchful waiting (7). However, the effectiveness of ERTN in this group has been only sparsely studied.END is associated with several complications such as nerve damage, seroma, and infections, which can be avoided by replacing END with ERTN. An argument for performing an END concurrently with resection of the primary tumour is to keep the total treatment time as short as possible. However, as ERTN can be administered alongside postoperative radiotherapy to the primary tumour site, it will not prolong the total treatment, but instead give the opportunity to decide on the need for adjuvant treatment of the neck when the pathology report from the surgery of the primary tumour is available (5,(8)(9)(10)(11)(12)(13)(14). At the Head and Neck Oncology Centre of the University Hospital in Örebro, the routine treatment of cN0 OSCC has been to use ERTN as the single adjuvant neck treatment, and to do END only in connection with free flap reconstructive surgery.A quality register has been kept since 1988, continuously collecting data on all head and neck cancer patients receiving any treatment at Örebro University Hospital in Sweden,
3489This article is freely accessible...